AlHarbi, Mohammed
Othman, Abdullah
Nahari, Ahmed Ali
Al-Jedai, Ahmed Hamdan
Cuadras, Daniel
Almalky, Faisal
AlAzmi, Fayez
Almudaiheem, Hajer Yousef
AlShubrumi, Hamad
AlSwat, Hameed
AlSahafi, Homaid
Sindi, Kamelia
Basaikh, Khadija
AlQahtani, Majed
Lamotte, Mark
Yahia, Moataz
Hassan, Mohamed El-Khedr
AlMutlaq, Mohammed
AlRoaly, Mohammed
AlZelaye, Somaya
AlGhamdi, Zein
Funding for this research was provided by:
Novo Nordisk, Saudi Arabia
Article History
Received: 3 November 2023
Accepted: 13 December 2023
First Online: 19 January 2024
Declarations
:
: IQVIA, the employer of Mark Lamotte and Daniel Cuadras, received consulting fees from NovoNordisk to conduct the current research. Mohammed AlHarbi, Abdullah Othman, Ahmed Ali Nahari, Ahmed Hamden Aljedai, Faisal Almalky, Fayez AlAzmi, Hajer Yousef Almudaiheem, Hamad AlShubrumi, Hameed AlSwat, Homaid AlSahafi, Kamelia Sindi, Khadija Basaikh, Majed AlQathani, Moataz Yahia, Mohamed El-Khedr Hassan, Mohammed AlMutlaq, Mohammed AlRoaly, Somaya AlZelaye, and Zein AlGhamdi. There is no conflict of interest to declare for the other authors.
: This study was conducted in accordance with the ethical principles derived from international ethics guidelines, including the Declaration of Helsinki, and the International Council for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP), all applicable laws, rules, and regulations. Consistent with local regulations and prior to the enrolment of patients, the study received approval from the Saudi MoH, independent ethics committee/institutional review board (IEC/IRB) (IRB log number 18-435, dated 28 August 2018). Only one central IRB was used for all the study sites. Since this research presented no more than minimal risk of harm to patients and involved no physical procedures with patients, informed consent was not required.